CNTB
Connect Biopharma Holdings Limited
Company Overview
| Mkt Cap | $172.39M | Price | $2.41 |
| Volume | 29.27K | Change | -1.63% |
| P/E Ratio | -11.0 | Open | $2.46 |
| Revenue | $26.0M | Prev Close | $2.45 |
| Net Income | $-15.6M | 52W Range | $0.70 - $3.82 |
| Div Yield | N/A | Target | $7.90 |
| Overall | 17 | Value | -- |
| Quality | 15 | Technical | 20 |
No chart data available
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Latest News
Analysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG), Insmed (INSM) and Connect Biopharma Holdings (CNTB)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CNTB | $2.41 | -1.6% | 29.27K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Connect Biopharma Holdings Limited Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW